glp 1 agonisten GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus New GLP-1 Guidelines for Type
Description
Most big pharma companies have at least one amylin in development, the most advanced of which is Novo Nordisks CagriSema, a dual amylin/GLP-1 agonist currently under FDA review
did not find any significant changes of renin, aldosterone, and urinary angiotensinogen after a single GLP-1 infusion in healthy men 28 and the same result was reported in patients with diabetes without kidney function impairment 32
Cardiovascular safety and benefits of GLP-1 receptor agonists
Approximately 57% of patients experienced decrease in appetite, which was consistent across the PIONEER trials [35,36,37,38,39,40,41,42,43,44]
The combined activation might trigger metabolic changes that neither hormone produces alone
